Lowe F C, Batista J, Berges R, Chartier-Kastler E, Conti G, Desgrandchamps F, Dreikorn K, O'Leary M, Perez M, Speakman M, Trachtenberg J, Tubaro A, Meesen B, Smets L, Stoevelaar H
1St Luke's-Roosevelt Hospital Center, New York, NY 10019, USA.
Prostate Cancer Prostatic Dis. 2005;8(3):206-9. doi: 10.1038/sj.pcan.4500806.
Disease progression has become an important issue for the management of lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH). Although several risk factors have been identified, no specific patient risk profiles have been established that can be useful in the day-to-day management of LUTS/BPH. In this study, an international panel of urologists developed a risk classification based on the attribution of a risk score to 243 unique patient profiles. From the perspective of clinical decision making, it was concluded that postvoid residual, symptom severity and maximum flow rate are the most relevant determinants of the risk of disease progression.
疾病进展已成为下尿路症状/良性前列腺增生(LUTS/BPH)管理中的一个重要问题。尽管已确定了多种风险因素,但尚未建立可用于LUTS/BPH日常管理的特定患者风险概况。在本研究中,一个国际泌尿外科专家小组根据对243种独特患者概况赋予风险评分,制定了一种风险分类。从临床决策的角度来看,得出的结论是,排尿后残余尿量、症状严重程度和最大尿流率是疾病进展风险最相关的决定因素。